5α-reductase type 1 modulates insulin sensitivity in men

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  Upreti, Rita ^a   Hughes, Katherine A ^a   Livingstone, Dawn E W ^a   Gray, Calum D ^b   Minns, Fiona C ^c   Macfarlane, David P ^a   Marshall, Ian ^a   Stewart, Laurence H ^c   Walker, Brian R ^a   Andrew, Ruth ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; ADIPOSE TISSUE; ADULT; AGED; AGED, 80 AND OVER; AZASTEROIDS; BLOOD GLUCOSE; BODY COMPOSITION; DOUBLE-BLIND METHOD; FINASTERIDE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; YOUNG ADULT;

EID: 84905712294     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1395     Document Type: Article

References (35)

1. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5-reductase 2 gene in male pseudohermaphroditism. Nature. 1991;354:159-161.
2. Russell DW, Wilson JD. Steroid 5-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61.
3. Wake DJ, Strand M, Rask E, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf). 2007;66:440-446.
4. Pöllänen E, Sipilä S, AlenM, et al. Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre- and postmenopausal women. Aging Cell. 2014;10:650-660.
5. Frye SV. Discovery and clinical development of dutasteride, a potent dual 5-reductase inhibitor. Curr Top Med Chem. 2006;6:405-421.
6. Tian G. In vivo time-dependent inhibition of human steroid 5- reductase by finasteride. J Pharm Sci. 1996;85:106-111.
7. Kotelevtsev YV, HolmesMC, Burchell A, et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycemia on obesity and stress. Proc Natl Acad Sci U S A. 1997;94:14924-14929.
8. Morton NM, Holmes MC, Fiévet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11β-hydroxysteroid dehydrogenase 1 knockout mice. J Biol Chem. 2001;276:41293-41300.
9. Dowman JK, Hopkins LJ, Reynolds GM, et al. Loss of 5-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536-4547.
10. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007; 92:1659-1665.
11. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: method for quantifying insulin-secretion and resistance. Am J Physiol. 1979;237:E214-E223.
12. Roddie IC, Shepherd JT. The blood flow through the hand during local heating, release of sympathetic vasomotor tone by indirect heating, and a combination of both. J Physiol (Lond). 1956;131: 657-664.
13. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001; 12(2-3):141-152.
14. VanhammeL, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. Journal of Magnetic Resonance. 1997;129(1): 35-43.
15. Upreti R, Homer NZ, Naredo G, et al. Measurement of tamsulosin in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;930: 121-128.
16. Best R, Walker BR. Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clin Endocrinol (Oxf). 1997;47:231-236.
17. Stimson RH, Mohd-Shukri NA, Bolton JL, Andrew R, Reynolds RM, Walker BR. The postprandial rise in plasma cortisol in men is mediated by macronutrient-specific stimulation of adrenal and extra- adrenal cortisol production. J Clin Endocrinol Metab. 2014;99: 160-168.
18. Goedecke JH, Evans J, Keswell D, et al. Reduced gluteal expression of adipogenic and lipogenic genes in Black South African women is associated with obesity-related insulin resistance. J Clin Endocrinol Metab. 2011;96:E2029-E2033.
19. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes. 2005;54:872-879.
20. Hong SK, Min GE, Ha SB, et al. Effect of the dual 5-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int. 2010;105:970-974.
21. Andriole GL, Kirby R. Safety and tolerability of the dual 5-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82-88.
22. Gravas s, Oelke M. Current status of 5-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010;28:9-15.
23. Sedgewick P. Statistical question: the Hawthorne effect. Br Med J. 2012;344:D8262.
24. McInnes KJ, Smith LB, Hunger NI, Saunders PT, Andrew R, Walker BR. Impaired glucose homeostasis in mice with adipose-specific deletion of the androgen receptor is associated with elevated retinol binding protein-4. Diabetes. 2012;61:1072-1081.
25. Godoy A, Kawinski E, Li Y, et al. 5-Reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011;71:1033-1046.
26. Uemura M, Tamura K, Chung S, et al. Novel 5-steroid reductase (SRD5A3, type 3) is overexpressed in hormone refractory prostate cancer. Cancer Sci. 2008;99:81-86.
27. Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011;17:5844-5849.
28. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179-2184.
29. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999;47:53-58.
30. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
31. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective study of Pima Indians. N Engl J Med. 1993;329:1988-1992.
32. Ma X, Becker D, Arena VC, Vicini P, Greenbaum C. The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis. J Clin Endocrinol Metab. 2009;94:2446-2451.
33. Boden G, Chen X, Desantis RA, Kendrick Z. Effects of age and body fat on insulin resistance in healthy men. Diabetes Care. 1993;16: 728-733.
34. MoulS, McVaryKT.Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol. 2010;20:7-12.
35. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562-2568.